Maintenance Anti-PD-1 Monoclonal Antibody + Capecitabine to Treat Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
Surgery with integrated treatment for metastatic colorectal cancer (mCRC) has created a new
clinical setting known as mCRC with no evidence of disease (NED). However, these patients
have a high risk of developing persistent cancer. This study aimed to investigate the
efficacy and safety of anti-PD-1 monoclonal antibody combined with capecitabine as a
maintenance treatment for patients with mCRC-NED.